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Abstract
Background: CD8 lymphocytes play an important role in the pathogenesis of COPD. Corticosteroids and
phosphodiesterase 4 (PDE4) inhibitors are anti-inflammatory drugs used for COPD treatment. Little is known of
the combined effect of these drugs on COPD CD8 cells. We studied the effect of corticosteroid combined with
PDE4 inhibitors on cytokine release form circulating and pulmonary CD8 cells, and on glucocorticoid (GR) nuclear
translocation.
Methods: The effect of dexamethasone alone and in combination with the PDE4 inhibitors roflumilast and
GSK256066 on cytokine release from circulating and pulmonary CD8 cells was measured. The effect of the
compounds on nuclear translocation of GR and cyclic AMP-responsive element-binding protein (CREB) was studied
using immunofluorescence.
Results: Dexamethasone inhibited cytokine release from COPD CD8 cells in a concentration dependent manner.
PDE4 inhibitors enhanced this anti-inflammatory effect in an additive manner. PDE4 inhibitors did not increase
corticosteroid induced GR nuclear translocation. PDE4 inhibitors, but not corticosteroid, increased phospho-CREB
nuclear translocation.
Conclusion: The combination of corticosteroids and PDE4 inhibitors results in an additive anti-inflammatory effect
in COPD CD8 cells. This enhanced anti-inflammatory effect could translate to important clinical benefits for patients
with COPD.
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Background
Chronic Obstructive Pulmonary Disease (COPD) is
characterised by airflow obstruction and an abnormal
inflammatory response to the inhalation of noxious
particles, most commonly from cigarette smoking [1].
Lymphocytes play a key role in this inflammatory
response; in particular, CD8 cell numbers are increased
in the lungs of COPD patients [2–4]. These cells are
capable of secreting pro-inflammatory cytokines and
cytotoxic molecules such as perforin and granzymes that
cause cell death [5, 6].
Inhaled corticosteroids (ICS) are widely used anti-
inflammatory treatments for COPD. These drugs bind to
the cytoplasmic glucocorticoid receptor (GR), forming a
complex that translocates to the nucleus, thereby
suppressing the activity of transcription factors such as
nuclear factor kappa-light-chain-enhancer of activated B
cells (NF-κB) that promote inflammatory gene transcrip-
tion [7]. ICS are used primarily to prevent exacerbations
in COPD patients with a history of exacerbations [8].
Phosphodiesterase 4 (PDE4) inhibitors are the only
new class of anti-inflammatory therapy to be licensed
for COPD in recent years. PDE4 inhibitors decrease
degradation of cyclic adenosine monophosphate (cAMP)
in immune cells, leading to a reduction in pro-
inflammatory activity. Roflumilast is the only currently
licensed PDE4 inhibitor, and is used to prevent
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exacerbations in severe COPD patients with a history of
exacerbations and chronic bronchitis [9, 10]. This PDE4
inhibitor is an oral treatment that can have systemic side
effects such as weight loss and gastro-intestinal disturb-
ance. This had led to efforts to develop inhaled PDE4 in-
hibitors, such as GSK256066, in order to improve the
therapeutic index [11].
Roflumilast and ICS target different cell signalling
pathways, and it has been shown combining these drugs
in vitro, using healthy human peripheral blood mono-
nuclear cells (PBMCs) and COPD bronchial epithelial
cells, results in an additive anti-inflammatory effect [12, 13].
These in vitro findings are mirrored by the results from
the recently published REACT clinical trial, which
showed a reduction in exacerbation rates when roflu-
milast was added to ICS (plus long acting bronchodila-
tor) treatment in COPD patients who were frequent
exacerbators [14].
We have further investigated the anti-inflammatory
potential of combining corticosteroids and PDE4
inhibitors, by using COPD lymphocytes. We focused on
CD8 cells, studying the effects of these drugs alone and
in combination on lymphocyte cytokine production. We




COPD patients, smokers with normal lung function (S)
and healthy non-smokers (HNS) were recruited to
obtain blood CD8 cells and PBMCs. COPD was diag-
nosed in accordance with the GOLD strategy document
[1]. A separate group of patients who were undergoing
lung resection for known or suspected lung cancer were
recruited to obtain lung tissue from which to isolate
pulmonary CD8 cells. Table 1 shows the patient demo-
graphics. The studies performed were approved by the
local research ethics committee (South Manchester Re-
search Ethics Committee, reference: 03/SM/396). All
subjects gave written informed consent.
Isolation of cells
PBMCs were isolated by Ficoll-Paque (GE Healthcare,
Bucks, UK) density gradient. Circulating CD8 cells were
isolated from PBMCs using positive selection CD8
microbeads (Miltenyi Biotec, Bisley, UK) in accordance
with manufacturer’s instructions.
Pulmonary CD8 cells were isolated as previously de-
scribed [15]. Briefly, lung tissue was homogenised in a
blender. An enriched population of lymphocytes was ob-
tained by Percoll (GE Healthcare) density gradient at
percoll concentrations of 40 and 70 %. CD8 cells were
positively selected from the enriched population of
pulmonary lymphocytes using positive selection CD8
microbeads (Miltenyi Biotec).
Cell culture
PBMCs and peripheral blood CD8 cells were seeded in
triplicate in 96 well plates at 100,000 cells per well.
Pulmonary CD8 cells were seeded at 50,000 cells per well.
Cells were pre-treated for 1 h with dexamethasone
(10−6 M – 10−10 M) alone or in combination with
GSK256066 (Stratech, Newmarket, UK, Spain), roflumilast
(Sigma-Aldrich, Poole, UK) or forskolin (Sigma-Aldrich).
Cells were then stimulated for 24 h with anti-CD2/3/28
beads (Miltenyi Biotec). Supernatants were harvested and
stored at −20 °C until ELISA was performed.
Cytokine analysis
Supernatants were analysed by ELISA according to
manufacturer’s instructions; IL-2 (R&D Systems DuoSet,
R&D Systems, Abingdon, UK), IFNγ (Ready-Set-Go Kit,
eBioscience, Herts, UK). Lower limits of detection were
15.6 pg/ml and 4 pg/ml for IL-2 and IFNγ respectively.
Table 1 Subject demographics
Peripheral blood CD8 Pulmonary CD8
COPD(17) S(10) HNS(7) COPD(6) S(4)
Age (yrs) 62.6 (45–72) 51.9 (38–75) 55.8 (44–69) 58.7 (43–73) 61.3 (50–68)
Male/Female 14/3 3/7* 2/5* 5/1 4/0
FEV1 (L) 1.5 (0.09) 3.0 (0.34)* 3.06 (0.35)* 1.75 (0.24) 3.11 (0.56)*
FEV1 % predicted 53.6 (3.5) 96.1 (3.83)* 99.6 (6.23)* 58.7 (9.7) 104.4 (11.8)*
FEV1: FVC (%)* 47.2 (2.8) 79.1 (1.89)* 79.1 (2.87)* 58.9 (8.4) 76.7 (8.9)*
Current Smoker 8 5 0* 3 4
Smoking History (pkyr) 42 (5.3) 17.6 (4.0)* 0* 42.4 (15.5) 36 (25.7)
ICS 10 0* 0* 2 0*
Data presented as mean (SD) or median (range). Data for all experiments are combined in this table. There were no significant differences between demographics
of subsets of volunteers for individual experiments. PBMC samples were paired with peripheral blood CD8 cells. Therefore separate demographics for PBMCs not
displayed. Statistically significant differences between COPD and other patient groups are indicated by *p < 0.05. COPD: chronic obstructive pulmonary disease;
S: smoker with normal lung function; HNS: healthy non-smoker; FEV1: Forced expiratory volume in 1 s; FVC: forced vital capacity; ICS: inhaled corticosteroids
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Immunofluorescence
Cytospins were prepared, air dried and fixed in 4 %
paraformaldehyde. Cells were labelled for Glucocortic-
oid receptor alpha (GR, thermoscientific PA1-516) or
phospho-CREB (Cell signalling #9191 s). Nuclei were
counterstained with 4′6-diamidino-2-phenylindole (DAPI).
Digital micrographs were obtained using a Nikon Eclipse
80i microscope equipped with a QImaging digital camera
and ImagePro Plus 5.1 software (MediaCybernetics,
Marlow, UK). Quantification of the nuclear region was
determined using the mean fluorescence intensity (MFI)
acquired by ImagePro Plus 5.1 software. Background
fluorescence levels were subtracted and nuclear MFI was
normalised to basal levels in order to calculate relative
changes.
Statistics
Data was analysed in GraphPad Prism and statistics
performed in GraphPad Instat (GraphPad Software,
SanDiego, CA, USA; http://www.graphpad.com). Cytokine
data were normally distributed. ANOVA was performed
to compare drug effects; where ANOVA p < 0.05, pairwise
comparisons were made using Bonferroni multiple
comparisons test.
Concentration response curve fitting was performed
using least squares nonlinear regression. EC50 and IC50
were calculated using Graphpad Prism from the fitted
concentration response curves.
Interaction ratios were calculated from the ratio of
observed efficacy (IO) to expected efficacy (IE). The ex-
pected efficacy was calculated using the Abbott formula:
IE ¼ Aþ B− AB=100ð Þ
when A is efficacy of compound A and B is efficacy of
compound B.
An interaction ratio between 0.5 and 1.5 is consistent
with an additive effect [16].
Results
Anti-inflammatory effects on blood lymphocytes
The concentration response effect of GSK256066, roflu-
milast and forskolin on IL-2 release from PBMCs was
studied in order to choose concentrations for further
experiments (Additional file 1 and Additional file 2:
Figure S1). The following concentrations were selected
for further experiments; GSK256066: 10−9M; roflumi-
last: 10−7M; forskolin: 10−6M. These concentrations
were selected as they were below the maximum effect
concentration (Emax) but were around the IC50 value
thus ensuring pharmacological activity.
PBMCs and circulating CD8 cells were isolated from
COPD patients (n = 13), S (n = 8) and HNS (n = 7). Basal
levels of IL-2 and IFNγ were low for all groups. Anti-
CD2/3/28 beads significantly increased the production
of both IL-2 and IFNγ from CD8 cells and PBMCs
(Additional file 1: Table S1). There were no significant
differences between subject groups in levels of cytokine
release from CD8 cells. In PBMCs, levels of stimulated
IL-2 release were higher in S (mean 6414.6 pg/ml) and
HNS (mean 6327.2 pg/ml) compared to COPD (mean
2469.3 pg/ml), p ≤ 0.05 for both comparisons.
Dexamethasone inhibited both IL-2 and IFNγ release
from peripheral blood CD8 cells and PBMCs in a con-
centration dependent manner (Figs. 1 and 2). Inhibition
at the highest dexamethasone concentration (10−6 M)
ranged from 61.1 to 68.5 % for IL-2 and from 56.3 to
59.7 % for IFNγ in the different subject groups (Emax
values are shown in Table 2). The inhibitory effect of
dexamethasone was not statistically different between
subject groups (ANOVA p > 0.05 for all concentrations
of dexamethasone). Table 2 shows that the IC50, EC50
and Emax values were numerically similar between
groups.
GSK256066 (10−9 M), roflumilast (10−7 M) and forsko-
lin (10−6 M) each caused significant inhibition of both
IL-2 and IFNγ release from stimulated peripheral blood
CD8 cells and PBMCs. The inhibitory effects of these
compounds was generally <60 % (Figs. 1 and 2; data
points on graphs where log[Dex] = 0).
Dexamethasone combined with GSK256066, roflumi-
last or forskolin resulted in greater inhibition of cytokine
release in all subject groups (Figs. 1 and 2, Table 2,
Additional file 1: Table S2). This enhanced inhibition
was significantly greater than the effect of corticosteroid
alone (ANOVA p < 0.05, Bonferroni p < 0.05) for all
conditions except for the dexamethasone 10−10 M
concentration for both IL-2 and IFNγ from CD8 cells.
The EC50 and IC50 values were generally lower for
dexamethasone combined with GSK256066, roflumilast
or forskolin compared to dexamethasone alone in all
subject groups (Table 2). Similarly, the Emax values for
combination treatments were greater than dexametha-
sone alone. Calculated interaction ratios were consistent
with an additive effect (for example at dexamethasone
10−8 M the majority of IR values ranged from 1.0-1.5
for both PBMCs and CD8 cells; see Additional file 1:
Table S2).
Anti-inflammatory effects on pulmonary CD8 cells
Pulmonary CD8 cells were isolated from lung tissue of
COPD patients (n = 6) and S (n = 4). Due to limited cell
numbers these experiments were limited to a single
PDE4 inhibitor. We selected GSK256066 as it was the
most potent in the previous experiments (See Additional
file 1: EC50 data). Basal levels of IL-2 and IFNγ release
from pulmonary CD8 cells were low. Anti-CD2/3/28
beads induced a significant increase in release of both
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IL-2 and IFNγ from pulmonary CD8 cells (Additional
file 1: Table S1). There were no significant differences
between patient groups in levels of cytokine release from
pulmonary CD8 cells (p > 0.05 for both IL-2 and IFNγ).
GSK256066 significantly inhibited release of both IL-2
(mean percent inhibition 40.1 % in S, 47.9 % in COPD)
and IFNγ (mean percent inhibition 28.5 % in S, 45.8 %
in COPD) from pulmonary CD8 cells with no significant
differences between patient groups (Fig. 3). Dexametha-
sone inhibited cytokine release from pulmonary CD8
cells in a concentration dependent manner with mean
inhibition at the highest concentration for IL-2 of 74.1
and 63.5 % for S and COPD respectively and IFNγ of
68.2 and 48.0 % for S and COPD respectively (Fig. 3).
There were no significant differences in effect of
dexamethasone between patient groups.
Dexamethasone combined with GSK256066 produced
a greater anti-inflammatory effect than dexamethasone
alone in both subject groups (Fig. 3). This enhanced
anti-inflammatory effect was numerically apparent at
most concentrations, but did not always achieve statis-
tical significance. Interaction ratios ranged from 0.9 to
Fig. 1 The effect of PDE4 inhibitors with dexamethasone on IL-2 release from peripheral blood CD8 cells and PBMCs. Peripheral blood CD8 cells
and PBMCs from COPD (n = 13, a & b), Smoker (n = 8, c & d) and Healthy non-smokers (HNS, n = 7 e & f) were pre-treated for 1 h with various
concentrations of dexamethasone (Dex) alone (О) or in combination with GSK256066 (■), Roflumilast (♦) or Forskolin (▲). The effect of
GSK256066, roflumilast and forskolin alone is represented as log[Dex] = 0. Cells were stimulated for 24 h with anti-CD2/3/28 beads. Supernatants
were harvested and Interleukin 2 (IL-2) was measured by ELISA. Data presented as mean ± SE
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1.4 for all studied concentrations of dexamethasone
(Table 3). This is consistent with an additive effect for
dexamethasone and GSK256066 combined.
GR nuclear translocation
In resting blood CD8 cells from COPD patients (n = 5),
GR was predominantly visualised within the cytoplasm.
Treatment with dexamethasone resulted in nuclear
translocation of GR. Treatment with GSK256066 and
forskolin alone also produced nuclear translocation of
GR. Roflumilast alone had no effect on the sub-cellular
location of GR. The combination of dexamethasone with
GSK256066, roflumilast or forskolin did not result in
any greater level of nuclear GR compared to dexametha-
sone alone (Fig. 4).
CREB nuclear translocation
In unstimulated peripheral blood CD8 cells, dexametha-
sone had no significant effect on nuclear translocation of
p-CREB. In contrast, GSK256066 and forskolin increased
nuclear p-CREB localisation. The addition of dexa-
methasone to GSK256066 or forskolin had no additional
effect on p-CREB nuclear translocation compared to
GSK256066 alone (Fig. 5).
Fig. 2 The effect of PDE4 inhibitors with dexamethasone on IFNγ release from peripheral blood CD8 cells and PBMCs. Peripheral blood CD8 cells
and PBMCs from COPD (n = 13, a & b), Smoker (n = 8 c & d) and Healthy non-smokers (HNS,n = 7, e & f) were pre-treated for 1 h with various
concentrations of dexamethasone (Dex) alone (О) or in combination with GSK256066 (■), Roflumilast (♦) or Forskolin (▲). The effect of GSK256066,
roflumilast and forskolin alone is represented as log[Dex]M= 0. Cells were stimulated for 24 h with anti-CD2/3/28 beads. Supernatants were harvested
and Interferon gamma (IFNγ) was measured by ELISA. Data presented as mean ± SE
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Discussion
The combination of dexamethasone with PDE4 inhibi-
tors had an additive anti-inflammatory effect on both
circulating and pulmonary CD8 cells from COPD pa-
tients and controls. These drug classes can be used in
combination in clinical practice [14]; we show that this
clinical strategy causes additive anti-inflammatory effects
on a cell type involved in COPD inflammation. This
additive anti-inflammatory effect is due to PDE4 inhibi-
tors influencing cAMP signalling, which is not affected
by corticosteroids.
We used sub-maximal concentrations of the PDE4 in-
hibitors roflumilast and GSK256066 to evaluate interac-
tions with corticosteroid. In PBMCs, which contain both
CD4 and CD8 cells, and isolated CD8 cells, we observed
the same phenomenon; PDE4 inhibition provided an
additional anti-inflammatory effect on top of that caused
by dexamethasone. This resulted in a greater Emax
(maximal inhibitory effect) and a reduced EC50 value for
combination treatment. It is interesting that this additive
effect was present at the majority of corticosteroid con-
centrations, as it implies that this effect may also be
observed in clinical practice across a range of drug
concentrations. The use of forskolin, which is known to
increase cAMP levels, in these experiments provided
confirmation that the additive effect was due to the
combination of cAMP modulation with GR activation.
Previous work has suggested that cAMP signalling may
oppose glucocorticoid action [17, 18]. However, we show
that this does not occur in COPD lymphocytes, as an
additive effect is observed with simultaneous cAMP
modulation with GR activation.
The number of experiments possible with lung cells
was reduced due to the lower number of cells available.
We chose to only use GSK256066 for these experiments,
as it had been the most potent in our hands, which is
consistent with previous publications comparing this
drug to roflumilast [19]. The results from lung CD8 cells
showed the same pattern as blood, but the experimental
variability was greater and so statistical significance was
Table 2 Mean EC50, IC50 and Emax for dexamethasone alone
and in combination with PDE4 inhibitors in blood CD8 cells and
PBMCs
Dex Dex/256066 Dex/Rof Dex/Forsk
Mean EC50 IL-2
CD8 COPD 7.8 4.8 6.7 1.6
Smoker 16.6 5.4 6.1 14.1
HNS 11.2 5.4 7.7 2.7
PBMC COPD 8.91 11.4 4.2 2.2
Smoker 22.9 8.3 8.7 18.2
HNS 12.0 4.9 3.8 2.0
Mean EC50 IFNγ
CD8 COPD 10.0 4.0 5.0 1.6
Smoker 20.0 6.3 7.9 10.0
HNS 15.8 12.6 3.2 5.0
PBMC COPD 31.6 4.0 6.3 10.0
Smoker 20.0 10.0 7.9 15.8
HNS 10.0 4.0 2.5 2.5
Mean IC50 IL-2
CD8 COPD 7.9 5.5 7.1 1.8
Smoker 16.6 6.2 8.5 22.9
HNS 7.9 5.9 8.3 3.2
PBMC COPD 8.5 30.2 4.8 1.6
Smoker 22.9 6.6 9.3 33.9
HNS 10.7 5.5 6.5 3.1
Mean IC50 IFNγ
CD8 COPD 12.0 3.6 4.6 1.9
Smoker 18.2 8.1 7.4 11.0
HNS 21.4 8.1 3.6 0.8
PBMC COPD 33.1 5.0 8.5 9.8
Smoker 23.4 8.7 8.9 24.0
HNS 15.1 6.0 3.6 1.0
Emax IL2
CD8 COPD 67.9 78.1 78.2 86.6
Smoker 68.5 86.5 81.9 80.9
HNS 66.3 82.0 80.7 79.7
PBMC COPD 64.2 87.4 83.0 81.6
Smoker 61.1 84.8 79.2 84.1
HNS 61.9 84.3 75.9 77.5
Emax IFNγ
CD8 COPD 59.8 74.9 75.1 78.8
Smoker 59.2 77.6 72.9 76.6
HNS 56.3 70.5 65.4 75.4
Table 2 Mean EC50, IC50 and Emax for dexamethasone alone
and in combination with PDE4 inhibitors in blood CD8 cells and
PBMCs (Continued)
PBMC COPD 69.7 86.4 82.2 85.7
Smoker 66.0 84.0 83.6 75.4
HNS 61.0 83.2 82.9 73.7
Data presented mean nanomolar concentration for EC50 and IC50. Data
presented as mean percent inhibition for Emax. Dex: dexamethasone; 256066:
GSK256066;CD8: circulating CD8 cells; PBMC: peripheral blood mononuclear
cells; Rof: roflumilast; Forsk: forskolin; COPD: chronic obstructive pulmonary
disease; HNS: healthy non-smoker; IL-2: interleukin 2; IFNγ: interferon gamma;
EC50:concentration producing 50 % of maximal effect; IC50: concentration
producing reduction of 50 % relative to untreated stimulated levels;
Emax: Maximal inhibitory effect at dexamethasone 10
−6 M
Grundy et al. Respiratory Research  (2016) 17:9 Page 6 of 11
not reached for every concentration when analysing
whether two drugs had a greater effect than one. Never-
theless, our results overall show the potential for addi-
tive anti-inflammatory effects on COPD CD8 cells when
PDE4 inhibitors and corticosteroids are used together.
The calculation of the IR indicated additive, and not
synergistic, effects on cytokine production. Furthermore,
we saw no enhancement of ligand dependent GR nuclear
translocation by PDE4 inhibition. Previous studies in
lung cell lines, such as epithelium and airway smooth
muscle, have shown a synergistic effect when corticoste-
roids are combined with compounds that increase intra-
cellular cAMP levels [20–22]. We did not observe
synergy in lymphocytes, indicating that synergy between
PDE4 inhibitors and corticosteroids does not occur in all
cell types. Similarly, Toll-like receptor 3 stimulation of
COPD bronchial epithelial cells resulted in cytokine pro-
duction that was suppressed by PDE4 inhibition and
Fig. 3 The effect of GSK256066 with dexamethasone on cytokine release from pulmonary CD8 cells. Pulmonary CD8 cells from COPD (n = 6) and
smokers with normal lung function (n = 4) were pre-treated with various concentrations of dexamethasone (Dex) alone (О) or in combination
with GSK256066 (■). The effect of GSK256066 alone is represented as log[Dex]M = 0. Cells were then stimulated with anti-CD2/3/28 beads for
24 h. Supernatants were harvested and interleukin 2 (IL-2) and interferon gamma (IFNγ) were measured by ELISA. Data presented as mean ± 95 %
confidence intervals. a COPD, IL-2, b Smokers, IL-2, c COPD, IFNγ, d Smoker. IFNγ. Statistical significance of difference between dexamethasone
alone compared to dexamethasone with GSK256066 indicated by * p < 0.05
Table 3 Interaction ratios for combination of dexamethasone
and GSK256066 on pulmonary CD8 cells
COPD Smokers
Interaction ratio IL-2
Dex (M) 10−8 10−7 10−6 10−8 10−7 10−6
Io 57.3 69.9 81.1 64.0 78.1 83.8
IE 64.5 79.0 81.0 54.1 77.2 84.6
IR 0.9 0.9 1.0 1.2 1.1 1.0
Interaction ratio IFNγ
Dex (M) 10−8 10−7 10−6 10−8 10−7 10−6
Io 60.2 70.1 67.6 61.9 74.6 82.9
IE 50.7 70 71.9 44.4 70.4 77.2
IR 1.2 1.0 0.9 1.4 1.1 1.1
Data presented as percent inhibition relative to cells stimulated with anti-CD2/3/28 IO & IE.
IR is the ratio of IO to IE. COPD: chronic obstructive pulmonary disease; Dex: dexamethasone;
IL-2: interleukin 2; IFNγ: interferon gamma; IO: Observed inhibition; IE: Expected inhibition; IR:
interaction ratio. An interaction ratio between 0.5 and 1.5 is consistent with additive effect
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corticosteroid in an additive, and not synergistic, manner
[12]. This further supports the concept that additive or
synergistic interactions between these drugs classes vary
according to the cell type used, and whether these are
cell lines or freshly obtained primary cells from COPD
patients.
Ligand-independent nuclear translocation of GR is
known to occur in response to β2-adrenoreceptor ago-
nists [23]. Similar to PDE4 inhibitors, β2-adrenoreceptor
agonists also increase intracellular cAMP levels. We also
observed some evidence that PDE4 inhibition and for-
skolin (without corticosteroid) enhance GR nuclear trans-
location. Thus, it seems likely that cAMP has a direct
effect on GR nuclear translocation in lymphocytes. How-
ever, GR nuclear translocation caused by cAMP may not
result in enhanced GR anti-inflammatory activity, and it
would be necessary to study DNA binding of GR in re-
sponse to PDE4 inhibitors to understand this. Further-
more, there was no additive GR nuclear translocation
when PDE4 inhibitors were used with corticosteroids in
lymphocytes, indicating that this is not a mechanism that
causes additive anti-inflammatory effects.
PDE4 inhibitors, but not corticosteroid, increased nu-
clear p-CREB; this transcription factor is known to be
cAMP responsive. This observation provides evidence
that PDE4 inhibition modulates cell signalling pathways
that are unaffected by corticosteroids. cAMP is known
to regulate production of cytokines such as IL-2 [24, 25],
while corticosteroids suppress pro-inflammatory cyto-
kine transcription through transrepression mechanisms
such as interference with NF-κB activity [7]. The target-
ing of different signalling pathways offers the likely
Fig. 4 Effect of Dexamethasone and PDE4 inhibitors on nuclear translocation of Glucocorticoid Receptor. Peripheral blood CD8 cells from COPD
patients (n = 5) were untreated (basal), treated with GSK256066 (10−9 M), roflumilast (10−7 M), or forskolin (10−6 M) alone or treated with
dexamethasone (10−6 M, Dex) alone and in combination with GSK256066, roflumilast or forskolin. Cells were harvested after 60 min. Cells were
immunostained with rabbit anti-glucocorticoid receptor (GR) antibody (red). Nuclei were counterstained with 4′,6-diamidino-2-phenylindole (blue).
The nuclear mean fluorescence intensity (MFI) of GR was measured. Representative images of each experimental treatment are shown (a-g).
h Data is presented as mean ± SE GR nuclear MFI normalised to basal levels. Statistically significant increase in nuclear GR above basal is indicated
when *p < 0.05
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explanation for additive effects reported here when these
drug classes are combined. Beta agonists modulate
cAMP signalling, and there is evidence that roflumilast
interacts with beta-agonists in epithelial cells to enhance
corticosteroid effects. This is worthy of study in COPD
lymphocytes.
The anti-inflammatory effects of dexamethasone were
similar in COPD patients and controls, both in PBMCs
and CD8 cells from the blood and lung tissue. We have
previously reported similar corticosteroid sensitivity in
COPD and control CD8 cells from blood and lung tissue
[15]. In contrast, stimulated bronchoalveolar lavage lym-
phocytes, containing CD4 and CD8 cells, show de-
creased corticosteroid sensitivity in COPD patients
compared to controls [26]. This highlights the potential
of corticosteroid effects on COPD lymphocytes to differ
according to the anatomical location of the cells, and
possibly the ratio of CD4 and CD8 cells present.
CD8 cells are capable of playing a variety of pro-
inflammatory roles in COPD, such as the secretion of
pro-inflammatory cytokines and cytotoxic molecules
including perforin and granzymes [5, 6]. These cells are
commonly involved in the host response to pathogens
such as viruses and bacteria. COPD exacerbations are
often caused by viruses and bacteria, and are charac-
terised by an excessive pro-inflammatory response to the
pathogen [27]. The role of cytotoxic CD8 cells in the
response to virus infection is well known [28], and these
cells also produce a pro-inflammatory response to
bacteria; this has been demonstrated using COPD lung
CD8 cells [29]. Inhaled corticosteroids are used to pre-
vent the excessive immune response that occurs during
exacerbations. The pharmacological interaction demon-
strated in this paper may be useful for limiting any role
that CD8 cells play in the inflammatory cascade during
COPD exacerbations.
We used T-cell receptor stimulation to evaluate the
effects of drugs on CD8 cytokine production. CD8 cells
express TLR receptors [30], and it would be interesting
to investigate the effects of corticosteroids and PDE4
Fig. 5 The effect of dexamethasone and PDE4 inhibitors of nuclear translocation of phoshporylated-CREB. Peripheral blood CD8 cells were
isolated from 4 COPD patients. Cells were treated with GSK256066 (10−9 M) or forskolin (10−6 M) alone or dexamethasone (10−6 M) alone and in
combination with GSK256066 or forskolin. Cells were immunostained with rabbit anti-phospho-cAMP response element binding (pCREB, red).
Nuclei were counterstained with 4′,6-diamidino-2-phenylindole (blue). The nuclear mean fluorescence intensity (MFI) of pCREB was measured.
Representative images of each experimental condition (a-g). Data is presented as mean ± SE pCREB nuclear MFI (H). Statistically significant increase in
nuclear pCREB is indicated when * p < 0.05
Grundy et al. Respiratory Research  (2016) 17:9 Page 9 of 11
inhibitors on TLR stimulated CD8 cells. This could in-
clude a wider range of cytokines than those studied here,
such as IL-17, IL-13 and IL-10.
Stimulated IL-2 levels from PBMCs were lower in
COPD patients compared to controls. This pattern was
not observed for IFNγ secretion from PBMCs, nor were
there any differences between COPD patients and con-
trols for cytokine release from blood or lung CD8 cells.
The lower IL-2 levels from COPD PBMCs may be a false
positive finding in a relatively limited sample size, as
there was no other evidence for reduced cytokine pro-
duction in our other experiments. Other papers investi-
gating lymphocyte cytokine secretion from PBMCs have
produced varying results, with more evidence for in-
creased secretion from COPD cells [31–34].
Conclusions
Clinical data shows that roflumilast causes additional
clinical benefits when added to ICS in COPD patients
[14, 35]. Our COPD lymphocyte data indicates that the
combination of these drugs causes an additive anti-
inflammatory effect on lymphocyte cytokine production.
Given the important role of lymphocytes in the patho-
physiology of COPD, our results could represent one
mechanism by which the clinical benefit of combining
these drug classes occurs. Furthermore, our data support
combining these drug classes in order to increase the
magnitude of anti-inflammatory effect on COPD lung
cells.
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were harvested and interleukin 2 (IL-2) was measured by ELISA. Data
presented as mean ± SE % inhibition of IL-2. (PNG 43 kb)
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